







      
Carla Gras Guiteras 
Universitat de Barcelona 
Facultat de Farmàcia i Ciències de l’alimentació 
Departament de Biologia, Sanitat i Medi Ambient 
Secció de Microbiologia 
5 de Febrer de 2021 
 











ABSTRACT  1 
Nowadays, it is becoming increasingly apparent that gut microbiota plays an important role in the 2 
prevention and development of metabolic diseases. Several bacterial species habit the human 3 
intestine and live in symbiosis with the host. During the last decades, abundant evidence arose 4 
confirming an active role of the microbiota in human metabolism. Hence, the disruption of the 5 
gut ecosystem might promote the development of metabolic disorders. This review aims to 6 
elucidate the current evidence regarding the mechanisms through which the gut microbiota may 7 
contribute to the protection or development of metabolic diseases. It specifically focuses on 8 
obesity, type-2 diabetes mellitus (T2DM), cardiovascular disease (CVD), and the potential 9 
interventions involving microbiota for preventing metabolic diseases. 10 
Keywords: microbiota, metabolic disease, obesity, type-2 diabetes mellitus, cardiovascular 11 
disease, probiotics, prebiotics 12 
RESUMEN 13 
Actualmente, cada vez es más evidente el rol de la microbiota intestinal en la prevención y 14 
desarrollo de las enfermedades metabólicas. Existen una gran variedad de especies bacterianas 15 
que habitan el intestino humano y viven en simbiosis con el huésped. Durante las últimas 16 
décadas, ha surgido nueva evidencia confirmando el rol activo de la microbiota en el 17 
metabolismo humano. Por lo tanto, la disrupción del ecosistema intestinal parece que puede 18 
promover alteraciones metabólicas. El objetivo de esta revisión es elucidar la evidencia actual 19 
respecto los mecanismos a través de los cuales la microbiota puede contribuir en la protección o 20 




mellitus tipo 2, las enfermedades cardiovasculares y las potenciales intervenciones para prevenir 22 
estas enfermedades metabólicas a través de la microbiota. 23 
Palabras clave: microbiota, enfermedad metabólica, obesidad, diabetes mellitus tipo 2, 24 
enfermedad cardiovascular, probióticos y prebióticos. 25 
INTRODUCTION 26 
The human gut contains several microorganisms which are referred to as the microbiota. 27 
Colonization by these microbes seems to start prenatally, through transmission from mother to 28 
fetus (1). However, it varies along life due to different factors such as diet, environment, age-29 
related factors, antibiotics, exercise, or pathologies (2).  30 
The human gut harbors trillions of microorganisms. It is believed that a standard man has around 31 
38 billion bacteria in the colon, the part of the gut where most of the microbiota lives (3). 32 
Moreover, it is estimated that the microbiome has 150-fold more genes than the human genome, 33 
which is accompanied by a huge microbial diversity in the intestine (4). Regarding the similarity 34 
of the DNA sequences of the gene 16s rRNA, it is possible to classify the bacteria from the gut in 35 
five different phyla. Firmicutes and Bacteroidetes represent the two main phyla, involving 90% 36 
of the gut microbiota (3). However, there are three more phyla that include Actinobacteria, 37 
Proteobacteria, Fusobacteria, and Verrucomicrobia, this last one being recently discovered. 38 
Firmicutes are anaerobic, gram-positive bacteria that form spores and they mainly involve the 39 
genera Ruminococcus, Lactobacillus, Blautia, Clostridium, and Faecalibacterium. On the other 40 
hand, Bacteroidetes are mainly represented by Prevotella and Bacteroides, which are gram-41 




Actinobacteria, Proteobacteria, Verrucomicrobia, and Fusobacteria are Bifidobacterium, 43 
Enterobacteriaceae, Akkermansia, and Fusobacterium respectively (5,6)  44 
Microbiota composition is highly influenced by diet. The different gut microbial patterns are 45 
called enterotypes and they can be classified depending on the predominant bacterial cluster: 46 
Bacteroides (enterotype 1), which is the most prevalent among the population and it is associated 47 
with a diet rich in fat and proteins, Prevotella (enterotype 2), which is linked to a diet rich in 48 
carbohydrates (CH), and Ruminococcus (enterotype 3). Each enterotype includes bacteria that 49 
share similar functions (3). Although it is known that diet plays an important role in shaping the 50 
microbiota composition, it is difficult to establish which components of the food are more 51 
beneficial for microbial diversity (7).  52 
These last decades, microbiota and its composition have been a subject of study and debate. It is 53 
known that there is a microbial-host symbiosis which contributes to several metabolic and 54 
biological functions (8). Therefore, the disruption of the gut ecosystem can promote a wide 55 
variety of physiological disorders, leading to the development of metabolic diseases (1).  56 
METHODOLOGY 57 
This research was conducted by consulting three different databases: PubMed, Scopus, and 58 
Cochrane library. In order to establish the theoretical framework, the search was limited to 59 
systematic reviews and metanalysis from the last six years. However, this review includes 60 
scientific literature from the past 21 years with the purpose of providing wide coverage of the 61 
topic. The search was conducted in English and different terms and Boolean operators were used: 62 
microbiota AND metabolic diseases, microbiota AND obesity, GLP1 AND microbiota, nutrition 63 




AND microbiota AND obesity, GLP1 AND incretin effect, gut microbiota AND cholesterol, gut 65 
microbiota AND cardiovascular disease, prebiotics OR probiotics AND metabolic diseases, diet 66 
AND microbiota. Among all the results obtained, only the most relevant and suitable were 67 
selected by reading the title or the abstract in order to be included in the review. Considering that 68 
most of the evidence regarding gut microbiota and metabolic disorders comes from animal 69 
studies, these were included in the present manuscript. Notwithstanding, randomized clinical 70 
trials were prioritized aiming to obtain a higher level of scientific evidence. 71 
MICROBIOTA AND OBESITY 72 
Microbiota composition  73 
Several studies support the idea of obesity being associated with changes in the composition of 74 
the two predominant phyla in the gut. Obese individuals seem to have an increased proportion of 75 
Firmicutes and a decreased abundance of Bacteroidetes (9,10). On the contrary, weight loss 76 
seems to be linked to a reduction of the Firmicutes to Bacteroidetes ratio (11).  Firmicutes 77 
include several butyrate-producing species, which contributes to increasing energy harvesting 78 
from the diet in obese people (12). Furthermore, obese individuals have lower bacterial diversity 79 
and their gut microbiota is altered (9). 80 
What can also explain the dysbiosis associated with obesity is the variation of specific genera or 81 
bacterial species in the gut. Various studies found a reduced abundance of Bifidobacterium in 82 
obese individuals (13,14). On the other hand, Everard et al. (2013) showed that increased 83 
amounts of Akkermansia muciniphila inversely correlates with weight gain in mice and humans. 84 
They also found that its levels were decreased in type 2 diabetic mice (15). As it can be observed 85 




Butyrivibrio Methanobrevibacter, and Lactobacillus were typically found in individuals with a 87 
lean phenotype and an increased bacterial richness. In contrast, Campylobacter, Bacteroides, 88 
Anaerostipes, Dialister, Porophyromonas, Parabacteroides, Staphylococcus, and Ruminococcus 89 
were more prevalent in obese subjects with reduced bacterial richness (16). All these findings 90 
suggest that microbiota composition might contribute to obesity development or protection as 91 
well as obesity may affect microbiota composition.  92 
Energy extraction from the diet 93 
Most of the evidence regarding the role of the gut microbiota in metabolic diseases comes from 94 
germ-free (GF) animal models (17). For instance, various of these studies have confirmed the 95 
association between microbiota and weight gain. Turnbaugh et al. (2006) proved that 96 
conventionally raised (CR) mice developed more body fat than GF mice. Besides, body fat 97 
increase was higher in GF mice colonized by “obese microbiota” than in GF mice colonized by 98 
“lean microbiota”, which indicates that the first one has a higher capacity to harvest energy from 99 
the diet. (18).   100 
The gut microbiome has a special enzyme called glycoside hydrolase, which cannot be found in 101 
the human genome. This enzyme hydrolyzes non-digestible carbohydrates, contributing to 102 
increasing the energy that the host obtains from the diet, which is linked to an increment of 103 
weight gain. The products of the fermentation of carbohydrates (CH) are called short-chain fatty 104 
acids (SCFAs), the main ones being acetate, propionate, and butyrate. SCFAs constitute an 105 
important energy source for colonocytes and they also play a role in metabolism regulation (7). 106 
Not all the microorganisms in the gut have the same capacity of extracting energy from the diet. 107 
Obese microbiota is composed of bacterial species which have a greater capacity to harvest 108 




Low-grade chronic inflammation and obesity 110 
Obesity is a metabolic disease that is characterized by a low-grade chronic inflammation (17). 111 
Gut microbiota and permeability of the intestinal barrier play an essential role in its development. 112 
Lipopolysaccharide (LPS), which is a component of the cell-wall of gram-negative bacteria, can 113 
enter into the systemic circulation and cause endotoxemia. If the integrity of the gastrointestinal 114 
barrier is compromised, LPS can cross it through the leaky tight junctions. Nonetheless, LPS can 115 
also enter into circulation through chylomicrons, which are the responsible lipoproteins for 116 
dietary fat absorption (1). Once LPS crosses the gut epithelium, it activates toll-like receptor 4 117 
(TLR4), which triggers the release of pro-inflammatory cytokines and leads to activation of 118 
several inflammatory processes. Together, it results in insulin desensitization, inflammation of 119 
adipose tissue, increased intestinal permeability, and oxidative stress (19).  120 
Various studies have confirmed the association between diet and metabolic endotoxemia. Cani et 121 
al. (2007) proved that a 4-week high-fat diet (HFD) considerably increased LPS levels in plasma 122 
and LPS-containing gut microbiota. Their findings showed that inflammation caused by LPS can 123 
lead to body weight gain and diabetes (20). After treatment with antibiotics, metabolic 124 
endotoxemia was reduced in ob/ob mice and in mice fed with an HFD, followed by a reduction in 125 
glucose intolerance, inflammation, and weight gain (21).  126 
GUT MICROBIOTA AND TYPE 2 DIABETES 127 
Gut microbiota not only plays a role in obesity but also in other metabolic disorders. For instance, 128 
changes in gut microbial composition have been reported in type-2 diabetic patients. A Chinese 129 
cohort study conducted by Qin et al. (2012) established an association between T2DM and 130 




Eubacterium rectale, Roseburia intestinalis, Roseburia Inulinivorans, Faecalibacterium 132 
prausnitzii, and Clostridiales species (spp.) SS3/4, accompanied by an increase in opportunistic 133 
pathogens in type-2 diabetic patients (22). In addition, Zhang et al. (2013) also observed 134 
depletion of the abundance of butyrate-producing bacteria in pre-diabetes and T2DM patients 135 
(23). Considering that butyrate is an essential component for the maintenance of the integrity of 136 
the intestinal epithelium, it is reasonable to claim that the impairment of butyrate production 137 
detected in type-2 diabetic patients might be associated with the low-grade chronic inflammation 138 
which characterizes this disease. Such a link between gut microbiota and T2DM can be better 139 
appreciated in Figure 1. 140 
Incretin effect of GLP-1 141 
Incretins are a group of gut hormones which are secreted in response to food ingestion and they 142 
cause an increase in insulin release in a glucose-dependent manner. There are two incretin 143 
hormones secreted by the human gut: glucagon-like peptide-1 (GLP-1) and glucose-dependent 144 
insulinotropic peptide (GIP). Once they are released into the bloodstream, they interact with β-145 
pancreatic cells stimulating the secretion of insulin and they inhibit hepatic gluconeogenesis 146 
reducing the secretion of glucagon (24–26). Even though the incretin effect is reduced or absent 147 
in type-2 diabetic patients, the pancreas seems to remain responsive to GLP-1 but not to GIP 148 
(25). While supraphysiological dosages of GLP-1 administered intravenously can increase the 149 
secretion of insulin in diabetic subjects and improve glucose homeostasis, GIP does not cause the 150 
same response (24).  151 
Besides acting as an incretin hormone, GLP-1 has a wide variety of effects on the organism. For 152 
instance, it diminishes blood pressure, increases satiety, and reduces appetite, thus being 153 




reduce the food reward, avoiding overeating and preventing weight gain (27). What is more, 155 
GLP-1 reduces gut motility and gastric emptying, which slows glucose absorption, thus 156 
decreasing the peak of postprandial blood glucose levels (28). Therefore, considering the effects 157 
that GLP-1 has on glucose metabolism, scientific advances have led to the development of 158 
antidiabetic drugs based on the action of GLP-1, for instance, GLP-1 receptor agonists and 159 
dipeptidyl peptidase-4 inhibitors. 160 
GLP-1 and gut microbiota  161 
GLP-1 is encoded by the proglucagon gene and it is secreted by L-cells, which are 162 
enteroendocrine cells (EEC), in response to different stimuli. Nutrients of the diet can trigger its 163 
secretion, as well as hormonal factors, some dietary polyphenols (curcumin and anthocyanin), 164 
and some specific microbial metabolites (24). However, this review will only focus on the release 165 
of GLP-1 through the mechanism that involves gut microbiota. 166 
SCFA 167 
SCFA can interact with L-cells through specific G protein-coupled receptors (GPCR) and 168 
promote GLP-1 secretion. More specifically, SCFA are ligands of GPR41 and GPR43 (29). 169 
These receptors are highly expressed in L-cells and their activation by SCFA leads to the 170 
secretion of GLP-1. Tolhurst et al. (2012) observed that GPR43 and GPR41 knockout mice had 171 
reduced GLP-1 secretion in vivo and in vitro, together with glucose tolerance impairment (30). 172 
Furthermore, a cross-sectional study conducted by Müller et al. (2019) showed a positive 173 
association between circulating SCFA and GLP-1 concentration, lipolysis, and enhanced insulin 174 
sensitivity (31). Finally, Wang et al. (2020) reported that administration of probiotics to a group 175 




acid bacteria, Bifidobacterium, and Clostridium leptum. As a result, the insulin secretion was 177 
increased due to enhanced production of GLP-1 (32). Hence, the gut microbiota exerts a positive 178 
impact on glucose metabolism through SCFA. 179 
Secondary bile acids 180 
Bile acids (BAs) are molecules synthesized from cholesterol that are released into the gut aiming 181 
to facilitate the solubilization and absorption of dietary lipids and fat-soluble vitamins after meal 182 
ingestion (33). Once they are released into the intestinal lumen, microbial-derived bile salt 183 
hydrolases (BSH) deconjugate and dehydroxylate them, leading to the synthesis of secondary 184 
BAs. These play an important role in glucose metabolism through the activation of two receptors 185 
called farnesoid X receptor (FXR) and TGR5, which are expressed in EEC. The activation of 186 
FXR seems to have a positive impact on the regulation of peripheral insulin sensitivity through a 187 
mechanism which does not involve GLP-1 secretion. Nonetheless, the activation of TGR5 by 188 
secondary BA triggers the release of GLP-1, thus promoting insulin secretion and inhibiting 189 
glucagon release (28,33).  190 
GUT MICROBIOTA AND CARDIOVASCULAR DISEASE 191 
Nowadays, CVD is the main cause of mortality and disability in developed countries (34). As 192 
already known, gut microbiota interacts to target organs through the release of bacterial 193 
metabolites which can act like hormones. Consequently, dysbiosis contributes to the development 194 
of different metabolic disorders such as CVD (35). The exact mechanisms underlying this 195 
association have not been fully elucidated. Nonetheless, various links, which are summarized in 196 
Table 3, have been found between gut microbiota and CVD.  197 




Cholesterol metabolism and primary bile acid synthesis 199 
Hypercholesterolemia is one of the main risk factors associated with CVD. The liver and the gut 200 
are the two organs responsible for cholesterol homeostasis (36). In the liver, cholesterol can be 201 
converted to primary BAs. These are synthesized through two different mechanisms: the classical 202 
pathway, which produces most of BAs and is regulated by cholesterol 7α-hydroxylase 203 
(CYP7A1), and the acidic pathway (37). The expression of the key enzymes involved in BA 204 
production can be modulated by gut bacteria, mainly Lactobacillus and Bifidobacterium, which 205 
suggests a possible role of intestinal microbiota in the reduction of total cholesterol (TC) (38). 206 
The primary BAs produced in human hepatocytes are cholic acid (CA) and chenodeoxycholic 207 
acid (CDCA). Previous to excretion into the bile they are conjugated with glycine or taurine (37). 208 
Then, they are stored in the gallbladder and secreted into the duodenum after food intake. Most of 209 
the BAs are actively reabsorbed in the ileum via apical Na+-dependent transporter and released 210 
by OST-α/β into the portal vein, which will transport them back to the liver (39). This cycle is 211 
called enterohepatic circulation and it is repeated 4-5 times daily. Each cycle leads to the 212 
excretion of 5% of the BAs after bacterial modification in the colon. In order to compensate for 213 
the loss and maintain the BA pool size, an equivalent amount of BAs are consequently 214 
synthesized in the liver from cholesterol, thus leading to a reduction of TC (40). 215 
Secondary bile acids 216 
As already commented, some of the primary BAs secreted into the gut can undergo a series of 217 
modifications due to the activity of microbial enzymes, resulting in secondary BAs. Some of the 218 
genera which have been identified to have BSH activity are Bacteroides, Enterococcus, 219 




acid (DCA) and CDCA to lithocholic acid (LCA) (37). As a result of these modifications, the 221 
hydrophobicity of BAs increases as well as their pka, thus facilitating their excretion through 222 
feces. Since they are less efficiently reabsorbed, the amount of BAs excreted needs to be replaced 223 
by de novo synthesis from cholesterol (41).  224 
Conversion of cholesterol into coprostanol by gut microbiota 225 
Cholesterol absorption can be diminished via its conversion to coprostanol by gut 226 
microorganisms. Due to its structure, coprostanol is poorly absorbed in the gastrointestinal tract 227 
and easily excreted through feces (36). The rate of cholesterol-to-coprostanol conversion is 228 
highly influenced by gut microbiota composition, which explains why it exists interindividual 229 
variation (42). Bacteroides spp. strain D8 was shown to reduce cholesterol to coprostanol (43), as 230 
well as different strains of Lactobacillus and Bifidobacterium (44). What is more, some members 231 
of Lachnospiraceae and Ruminococcaceae families have also been associated with 232 
coprostanoligenic activity (45). However, bacterial enzymes involved in this biotransformation 233 
are still unknown (36). All in all, coprostanol has been linked to cholesterol elimination from the 234 
body, thus leading to a reduction of CVD risk (46). 235 
Role of gut microbiota in the development of atherosclerosis  236 
Gut microbiota is involved in the formation of trimethylamine (TMA), which can be oxidized in 237 
the liver to produce a pro-atherogenic compound called trimethylamine-N-oxide (TMAO). 238 
Intestinal bacteria can synthesize TMA from dietary precursors such as choline, betaine 239 
phosphatidylcholine, γ-butyrobetaine, crotonobetaine, carnitine,  and glycerophosphocoline (34), 240 
which are mainly found in red meat, eggs, and dairy products. In addition, fish and other seafood 241 




into TMAO are flavin monooxygenases (FMOs). FMO3 is the main isoform in the liver and it is 243 
also the one which shows the highest activity to produce TMAO (48). Clara et al. (2017) showed 244 
that subjects with higher TMAO production presented lower gut microbial diversity and higher 245 
Firmicutes:Bacteroidetes ratio (49). What is more, Kymberleigh et al. (2015) found that species 246 
belonging to Firmicutes and Proteobacteria phyla showed higher conversion activity from 247 
choline to TMA (50). These findings suggest that a low gut microbiota diversity, Firmicutes and 248 
Proteobacteria are associated with TMA production and therefore, to higher TMAO synthesis.  249 
Higher plasma TMAO levels have been clearly linked to atherosclerosis and increased 250 
cardiovascular risk (35). A recent metanalysis concluded that subjects with high TMAO levels 251 
have 62% more risk of suffering major adverse cardiovascular events (MACE) and 63% 252 
increased risk for all-cause death than subjects with low TMAO levels (51). What is more, Fu et 253 
al. (2017) investigated TMAO levels of patients with coronary artery disease and found that 254 
subjects with plaque rupture had higher concentrations of this compound than those with 255 
nonplaque rupture (52). Besides, it was observed that patients with unstable plaques showed an 256 
increase of Collinsella and a decrease of Eubacterium and Roseburia (53). 257 
Different mechanisms have been proposed to explain the association between TMAO and 258 
increased CV risk. For instance, Zhu et al. (2016) found that TMAO induces platelet aggregation 259 
in human cells in vitro (54). Furthermore, it leads to inflammatory gene expression and 260 
endothelial cell adhesion of leukocytes (55). On the other hand, TMAO seems to upregulate two 261 
scavenger receptors (SR), cluster of differentiation 36 (CD36) and SR-A1, which increase the 262 
uptake of modified LDL, thus promoting foam cell formation (56). Additionally, it was found 263 
that dietary TMAO supplementation in rodents not only decreases the expression of the key BA 264 




hepatic BA transporters expression. This effect causes a reduction of the bile acid pool size and 266 
results in lower reverse cholesterol efflux (57).  267 
Metabolic endotoxemia and its role in CVD 268 
CVD is characterized by increased intestinal permeability and higher levels of circulating LPS. It 269 
is known that LPS can trigger an inflammatory response which might enhance the formation of 270 
atherosclerotic plaque. (58).  Low-grade chronic inflammation caused by increased endotoxemia 271 
has been previously linked to CVD (59). For instance, Mclntyre et al. (2011) observed higher 272 
peripheral endotoxemia in patients with major CVD burden (60). Nevertheless, it is still not clear 273 
if CVD is the cause or the consequence of dysbiosis, gut barrier disruption, and the associated 274 
metabolic endotoxemia. 275 
POTENTIAL INTERVENTIONS 276 
There are different potential interventions for the prevention or treatment of metabolic diseases 277 
which involve the gut microbiota. In this review, only the role of probiotics, prebiotics, and diet 278 
will be deeply considered. 279 
Effect of probiotics in metabolic diseases 280 
It is well known that the consumption of probiotics has different benefits for the host. Food and 281 
Agriculture Organization of the United Nations (FAO) and the World Health Organization 282 
(WHO), define probiotics as “live microorganisms which, when administered in adequate 283 
amounts, confer a health benefit on the host” (61). A recent review concluded that specific strains 284 
of Lactobacillus such as L. casei, L. rhamnosus, L. plantarum, and L. gasseri, and some strains of 285 
Bifidobacterium including B. Breve, B. Infantis and B. longum, have anti-obesogenic effects and 286 




studies and in human studies (62). On the other hand, Pediococcus pentosaceus and Bacteroides 288 
uniformis CECT 7771 proved to reduce several obesity parameters in DIO mice (63,64). What is 289 
more, Akkermansia muciniphila was also identified to reduce fat-mass gain, insulin resistance, 290 
metabolic endotoxemia, and adipose tissue inflammation in rodents (15). Regarding the evidence 291 
in human subjects, Pediococcus pentosaceus and different strains of Bifidobacteria and 292 
Lacobacillus combined or on their own have proved to diminish body weight, fat mass, waist 293 
circumference and, BMI in human adults (65–69). Therefore, all the evidence suggests that 294 
certain probiotics have anti-obesogenic effects.  295 
Notwithstanding, some probiotic strains also ameliorate different parameters related to T2DM, 296 
especially those belonging to Bifidobacterium and Lactobacillus spp. For instance, 297 
supplementation with B. adolescentis or L. rhamnosus GG improved insulin sensitivity in HF-298 
diet-fed mice (70,71). Furthermore, supplementation of HFD-fed rats with B. longum reduced 299 
metabolic endotoxemia diminishing plasma LPS levels (72). Some other probiotics such as L. 300 
rhamnosus NCDC 17, L. casei CCFM419, L. plantarum MTCC5690 and Clostridium butyricum 301 
CGMCC0313.1 also proved to play an important role in the prevention of T2DM by increasing 302 
GLP-1 secretion in mice (73–76).   303 
Even though the current evidence is not as vast as in animal models, the anti-diabetic effects of 304 
certain probiotics have also been tested in humans. First of all, different randomized clinical trials 305 
(RCTs) confirmed that consumption of probiotic yoghurt containing B. animalis subsp lactis BB-306 
12 and L. acidophilus La-5 or L acidophilus, Lb. casei,  and B. bifidum, reduced several 307 
parameters related to diabetes such as Hb1Ac, fasting blood glucose levels, TG, TC, and 308 
antioxidant status (77,78). Another RCT proved that consumption of fermented milk containing 309 




control in T2DM patients (79).  On the other hand, consumption of L. reuteri DSM 17938 during 311 
twelve weeks enhanced insulin sensitivity in diabetic humans, as well as Lb. acidophilus NCFM 312 
(80,81). Altogether, this evidence leads to the conclusion that several probiotic strains might 313 
exert anti-diabetic effects both in animals and humans. 314 
On the other hand, certain probiotics seem to modulate some parameters related to cardiovascular 315 
risk such as low-grade chronic inflammation, obesity, hypertension, and hypercholesterolemia. 316 
According to Deng et al. (2017), the administration of Bacillus subtilis and Bacillus licheniformis 317 
attenuated the inflammation response caused by LPS in rats (82). On the other hand, several 318 
probiotic strains seem to exert hypocholesterolemic effects. One of the main mechanisms through 319 
which probiotics could reduce cholesterol levels is via BSH activity. Degirolamo et al., (2014) 320 
showed that administration of a mixture of probiotic strains called VSL#3 (B. breve, B. infantis, 321 
B. longum, L delbruekckii spp. bulgaricus, L. acidophilus, L. plantarum, L. casei, and 322 
Streptococcus salivarum spp.)  in mice, increased BA deconjugation and fecal excretion. (83). 323 
What is more, an RCT proved that administration of yoghurt containing microencapsulated BSH-324 
active L. reuteri 30242 to hypercholesterolemic adults, reduced LDL-cholesterol, TC, and apoB-325 
100 (84). Considering the evidence, BSH-active bacteria are currently being used as supplements 326 
aiming to reduce cholesterol levels and CVD risk (36,85).  327 
Finally, certain probiotics can diminish CV risk by reducing blood pressure. This ability is 328 
thought to result from the generation of bioactive peptides like ACE inhibitory peptides when 329 
fermenting some food products such as fermented milk, soymilk, yoghurts and cheese (85,86). It 330 
was detected that L. helveticus has anti-hypertensive effects (87–89). Similar results were 331 




rhamnosus (91), L. bulgaricus FTCC 411, and  L. fermentum FTD 13 (92). All in all, current 333 
evidence suggests that these probiotic strains might reduce CV risk by decreasing blood pressure. 334 
Effect of prebiotics in metabolic diseases 335 
FAO/WHO stated that “a prebiotic is a selectively fermented ingredient that allows specific 336 
changes, both in the composition and/or activity in the gastrointestinal microbiota that confers 337 
benefits upon host wellbeing and health” (93). There are several types of food ingredients which 338 
are considered prebiotics. The most important include inulin, oligosaccharides, 339 
galactooligosaccharides (GOS), fructooligosaccharides (FOS), xylooligosaccharides, resistant 340 
starch, and non-starch polysaccharides such as pectins, gums, mucilages, celluloses, and 341 
hemicelluloses (94). There is increasing evidence that consumption of foods rich in prebiotics 342 
might be beneficial for the prevention of metabolic diseases. The ingestion of these compounds 343 
can modulate the gut microbiota composition, mainly leading to an increase of Bifidobacterium 344 
spp. (5). It was reported that resistant starch presents a bifidogenic effect (95), which is 345 
negatively correlated with the development of obesity and T2DM (96). Furthermore, it improves 346 
gut barrier integrity, thus preventing LPS translocation and associated disorders (97).  347 
Evidence in humans is not as consistent as in animal studies since some contradictions arise. 348 
According to Cani et al. (2009), daily prebiotic consumption during 2 weeks, enhanced plasma 349 
concentrations of GLP-1 and peptide YY in healthy subjects, which might reduce appetite 350 
sensation and improve insulin response after a meal (98).  Administration of GOS to a group of 351 
overweight adults resulted in an improvement of TG, TC, and insulin levels as well as an increase 352 
in the abundance of Bifidobacterium spp. (99). In addition, oligofructose-enriched inulin caused a 353 
decrease in body weight, body fat, and fat trunk in overweight and obese children, accompanied 354 




proved to reduce fasting blood sugar, HbA1c, insulin resistance, and inflammatory markers such 356 
as hs-CRP, TNF-alpha, and LPS in diabetic females (101). Even though these results suggest that 357 
consumption of prebiotics might be protective against metabolic disorders, other studies show no 358 
effect on such parameters (102,103). Therefore, further studies in humans are needed in order to 359 
elucidate the role of prebiotics as a potential intervention for metabolic diseases. 360 
Gut microbiota modification by diet and its effect on metabolic diseases 361 
Several elements have been identified to alter the microbiota composition. Nevertheless, one of 362 
the main factors which can modulate gut microbiota is the diet, thus having an impact on the 363 
prevention or development of metabolic diseases. 364 
For instance, a protein-rich diet seems to improve gut bacterial richness, which has been 365 
previously linked to a healthy metabolic status (104,105). According to David et al. (2014), the 366 
ingestion of a diet based on animal protein increases the levels of Alistipes, Bactoroides, and 367 
Bilophila and it reduces the abundance of some Firmicutes spp. such as Ruminococcus Bromii, 368 
Roseburia, and Eubacterium Rectale  (106). On the other hand, it was observed that pea protein 369 
significantly elevates the number of Lactobacillus and Bifidobacterium spp. as well as increases 370 
the levels of SCFA, which are beneficial for the colonic epithelium (107).  371 
Regarding the consumption of fats, there is wide evidence suggesting that an HFD increases the 372 
risk of metabolic disorders. Nevertheless, the type of fat needs to be differentiated. Fava et al. 373 
(2013) conducted a large-scale dietary intervention which showed that a low-fat diet reduced 374 
cholesterol levels and fasting glucose concentrations and elevated fecal Bifidobacterium. In 375 
contrast, consumption of a high-saturated fat diet increased Faecalibacterium Prausnitzii. 376 




decreased total bacterial numbers, TC and, LDL in plasma (108). Moreover, it was observed that 378 
consumption of an HFD increases gut permeability, thus leading to the translocation of LPS and 379 
metabolic endotoxemia (20). Besides, dietary fat might facilitate the absorption of LPS through 380 
chylomicrons. Therefore, it is reasonable to claim that diets rich in fats may increase the risk of 381 
metabolic disorders since systemic endotoxemia is the basis for several metabolic diseases (109).  382 
Not only the effect of proteins and fats should be considered when talking about metabolic 383 
diseases but also the role of CH. On the one hand, non-digestible CH can resist degradation by 384 
intestinal enzymes. Therefore, they act as prebiotics and exert different effects on the organism 385 
which have been previously commented. On the other hand, it is known that high sugar diets 386 
promote the development of metabolic disorders (1). Nevertheless, it is becoming clearer that 387 
artificial sweeteners are not a healthier alternative to increase the sweet taste. Non-nutritive 388 
sweeteners (NNS) are artificial sweeteners which became increasingly popular as sugar 389 
substitutes since they offer a sweet taste without providing any calories or glycemic effects (110). 390 
Despite being the most used additives all around the world (111), there is growing evidence 391 
suggesting that NNS consumption can induce metabolic changes which might lead to obesity and 392 
T2DM (112). It was observed that consumption of NNS can increase Firmicutes to Bacteroidetes 393 
ratio as it often happens in an obese state (112). Moreover, Suez et al. (2014) proved that mice 394 
treated with water supplemented with NNS developed glucose intolerance. They obtained similar 395 
results with obese mice fed with an HFD and commercial saccharin. However, after the 396 
administration of antibiotics, glucose intolerance was reversed. In order to confirm the role of the 397 
gut microbiota, they performed fecal transplantations from mice treated with saccharin into germ-398 





All the evidence considered in this review suggests that gut microbiota is highly involved in the 401 
prevention and the development of metabolic diseases. The main mechanisms which underly 402 
such interaction are energy extraction from the diet, low-grade chronic inflammation, and 403 
intestinal peptides which can act like hormones.  404 
Not only certain microbial patterns seem to promote metabolic disorders, but also metabolic 405 
diseases seem to have an impact on the microbiota composition. One of the main microbial 406 
features which characterize obese people is that they show an increase in the Firmicutes to 407 
Bacteroidetes ratio. Some studies do not support this association, but it is important to note that 408 
they were conducted with small samples  (14,113). Therefore, the vast majority of the evidence 409 
suggests that obesity is linked to a higher Firmicutes to Bacteroidetes ratio, since Firmicutes spp. 410 
seem to have a greater capacity to extract energy from the diet (12). Interestingly, microbiota 411 
composition is also essential when talking about CVD. Bacteria with BSH activity can convert 412 
BAs into secondary BAs, leading to higher excretion of these molecules which need to be 413 
replenished by the novo synthesis from cholesterol. Hence, cholesterolemia is decreased as well 414 
as CVD risk. 415 
On the other hand, low-grade chronic inflammation is the basis of several metabolic diseases, and 416 
it is often enhanced by metabolic endotoxemia. One molecule responsible for this metabolic 417 
disorder is LPS, which is a component of the cell-wall of gram-negative bacteria. It might seem a 418 
paradox since, in an obese state, there is a reduction of Bacteroidetes, which are gram-negative 419 
bacteria, and an increase of Firmicutes, which are gram-positive bacteria (114). 420 
The last notorious mechanism through which gut microbiota plays a role in the prevention and 421 
development of metabolic diseases is the generation of several metabolites that can interact with 422 




released into the circulation and can exert an effect on the regulation of the host metabolism. For 424 
instance, GLP-1 is an incretin hormone whose presence is reduced or absent in T2DM. 425 
Nevertheless, SCFA-producing bacteria and bacteria with BSH activity might increase GLP-1 426 
secretion, thus having a positive impact on T2DM. Considering that these microorganisms seem 427 
to be reduced in type-2 diabetic patients, it raises the possibility of using probiotics as a potential 428 
intervention for T2DM. On the other hand, another bacterial metabolite that should be considered 429 
is TMA since it can be converted into TMAO, which is a pro-atherogenic compound that 430 
increases the cardiovascular risk (34). 431 
Therefore, it is clear that depending on its composition, gut microbiota may exert a positive or a 432 
negative effect on the host metabolism. In view of it, different potential interventions are 433 
currently being contemplated in order to modify the gut microbiota. These include probiotics, 434 
prebiotics and diet. The main probiotics which seem to have a positive effect on metabolic 435 
disorders are Lactobacillus spp. and Bifidobacterium spp. strains. Regarding prebiotic 436 
consumption, clear benefits have been detected in animal studies, but it exists controversy in 437 
humans. Some human studies detected no effect on metabolic parameters after consumption of 438 
some prebiotics such as GOS or oligofructose (102,103). Although most of the evidence indeed 439 
suggest prebiotics as a plausible intervention for preventing metabolic diseases (115), more 440 
quality RCTs are needed. On the other hand, diet exerts a direct effect on gut microbiota 441 
composition, which is why it should also be considered as a potential intervention. 442 
Altogether, current scientific data suggests an important role of the gut microbiota in the 443 
prevention and development of metabolic diseases. Nevertheless, it is important to note that most 444 
of the evidence comes from animal studies and some mechanisms need to be better understood. 445 
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Table 1 Bacterial phyla and their most predominant genera. 
PHYLA GENERA 
Firmicutes Ruminococcus, Lactobacillus, Blautia, Clostridium and Faecalibacterium 
Bacteroidetes Prevotella and Bacteroides 
Actinobacteria Bifidobacterium,  





Table 2 Microbiota composition associated to an obese state or a lean state. 
























Table 3 Microbiota composition associated to Cardiovascular disease. 
Risk of cardiovascular 
disease Reason Associated gut microbiota 




 Conversion of cholesterol into 
coprostanol 
Bacteroides spp. strain D8, 





 TMAO production 
Low gut microbial diversity, 
Firmicutes, Proteobacteria, 
Collinsella and a reduction of 
Eubacterium and Roseburia. 

























Type-2 diabetic patients experience a reduction of the abundance of SCFA-producing bacteria, which leads to a decrease of the 
integrity of the host intestinal epithelium, an increase of metabolic endotoxemia and a reduction of the synthesis of GLP-1. 
These alterations contribute to the promotion of T2DM. 
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